 David Wagner
Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CD40 Antigens | 21 | 2023 | 81 | 7.020 |
Why?
| | CD40 Ligand | 9 | 2023 | 37 | 1.830 |
Why?
| | CD4-Positive T-Lymphocytes | 9 | 2017 | 959 | 1.700 |
Why?
| | T-Lymphocyte Subsets | 5 | 2019 | 383 | 1.420 |
Why?
| | Diabetes Mellitus, Type 1 | 13 | 2019 | 3254 | 1.360 |
Why?
| | Multiple Sclerosis | 3 | 2022 | 372 | 1.190 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 2 | 2019 | 47 | 1.160 |
Why?
| | Mice, Inbred NOD | 14 | 2019 | 552 | 1.100 |
Why?
| | Autoimmunity | 8 | 2014 | 812 | 1.040 |
Why?
| | Peptides | 3 | 2023 | 848 | 1.020 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2017 | 127 | 0.960 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2022 | 25 | 0.810 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2022 | 69 | 0.770 |
Why?
| | T-Lymphocytes | 5 | 2013 | 1735 | 0.760 |
Why?
| | Forkhead Transcription Factors | 2 | 2013 | 170 | 0.680 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2017 | 309 | 0.650 |
Why?
| | Therapies, Investigational | 1 | 2018 | 14 | 0.610 |
Why?
| | Signal Transduction | 8 | 2023 | 4501 | 0.580 |
Why?
| | Oligopeptides | 1 | 2019 | 234 | 0.570 |
Why?
| | Cell Movement | 3 | 2017 | 863 | 0.550 |
Why?
| | Demyelinating Diseases | 1 | 2017 | 73 | 0.530 |
Why?
| | Mice | 19 | 2023 | 14841 | 0.530 |
Why?
| | Central Nervous System | 1 | 2017 | 230 | 0.480 |
Why?
| | Animals | 22 | 2023 | 31565 | 0.450 |
Why?
| | Flow Cytometry | 7 | 2017 | 1075 | 0.450 |
Why?
| | Cytokines | 4 | 2017 | 1824 | 0.440 |
Why?
| | fas Receptor | 1 | 2013 | 91 | 0.430 |
Why?
| | Biomedical Research | 1 | 2018 | 582 | 0.410 |
Why?
| | DNA-Binding Proteins | 2 | 2013 | 1311 | 0.400 |
Why?
| | CTLA-4 Antigen | 2 | 2012 | 76 | 0.400 |
Why?
| | Galectins | 1 | 2012 | 22 | 0.400 |
Why?
| | Membrane Microdomains | 2 | 2010 | 31 | 0.390 |
Why?
| | Autoantigens | 2 | 2012 | 396 | 0.380 |
Why?
| | Islets of Langerhans | 1 | 2017 | 728 | 0.370 |
Why?
| | Mice, Inbred BALB C | 6 | 2023 | 1144 | 0.360 |
Why?
| | Epitopes | 1 | 2012 | 434 | 0.340 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2010 | 73 | 0.340 |
Why?
| | CD4 Antigens | 2 | 2008 | 123 | 0.340 |
Why?
| | Homeodomain Proteins | 1 | 2013 | 463 | 0.340 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2010 | 140 | 0.330 |
Why?
| | Cell Proliferation | 5 | 2017 | 2173 | 0.330 |
Why?
| | Adoptive Transfer | 3 | 2017 | 194 | 0.320 |
Why?
| | Immune Tolerance | 2 | 2012 | 321 | 0.320 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2008 | 337 | 0.310 |
Why?
| | TNF Receptor-Associated Factor 2 | 1 | 2008 | 8 | 0.310 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 66 | 0.300 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2013 | 615 | 0.290 |
Why?
| | Platelet Membrane Glycoprotein IIb | 1 | 2007 | 4 | 0.290 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2006 | 13 | 0.270 |
Why?
| | Interferon-gamma | 3 | 2017 | 719 | 0.270 |
Why?
| | Spleen | 3 | 2017 | 485 | 0.240 |
Why?
| | Trypanosoma cruzi | 1 | 2023 | 23 | 0.220 |
Why?
| | Genes, RAG-1 | 1 | 2003 | 11 | 0.220 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 2023 | 31 | 0.210 |
Why?
| | Chagas Disease | 1 | 2023 | 32 | 0.210 |
Why?
| | Autoimmune Diseases | 2 | 2003 | 381 | 0.210 |
Why?
| | Integrins | 1 | 2023 | 79 | 0.200 |
Why?
| | Blotting, Western | 2 | 2017 | 1143 | 0.200 |
Why?
| | Mice, Inbred C57BL | 5 | 2019 | 4680 | 0.200 |
Why?
| | Immunomodulation | 2 | 2012 | 84 | 0.190 |
Why?
| | Mice, SCID | 2 | 2017 | 312 | 0.180 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 898 | 0.170 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2321 | 0.170 |
Why?
| | Lymphocyte Activation | 2 | 2017 | 1036 | 0.170 |
Why?
| | Amino Acids | 1 | 2023 | 445 | 0.160 |
Why?
| | CD28 Antigens | 2 | 2017 | 47 | 0.160 |
Why?
| | Mice, Knockout | 2 | 2017 | 2562 | 0.160 |
Why?
| | Biomarkers | 2 | 2022 | 3397 | 0.160 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2021 | 179 | 0.160 |
Why?
| | Female | 10 | 2021 | 59325 | 0.160 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 159 | 0.150 |
Why?
| | Phenotype | 2 | 2017 | 2784 | 0.150 |
Why?
| | Freund's Adjuvant | 1 | 2017 | 17 | 0.140 |
Why?
| | Cell Survival | 2 | 2012 | 1014 | 0.140 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 714 | 0.140 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2017 | 44 | 0.140 |
Why?
| | Immunologic Memory | 1 | 2019 | 313 | 0.140 |
Why?
| | Cell Separation | 2 | 2014 | 290 | 0.130 |
Why?
| | Disease Models, Animal | 2 | 2017 | 3498 | 0.120 |
Why?
| | Precision Medicine | 1 | 2018 | 335 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2017 | 415 | 0.120 |
Why?
| | Cell Division | 2 | 2008 | 754 | 0.120 |
Why?
| | Spinal Cord | 1 | 2017 | 344 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 926 | 0.110 |
Why?
| | Ku Autoantigen | 1 | 2013 | 13 | 0.110 |
Why?
| | Antigens, Nuclear | 1 | 2013 | 19 | 0.110 |
Why?
| | Thymocytes | 1 | 2013 | 28 | 0.110 |
Why?
| | HLA-DR Antigens | 1 | 2014 | 219 | 0.100 |
Why?
| | Peptide Fragments | 1 | 2017 | 665 | 0.100 |
Why?
| | Interleukin-17 | 1 | 2013 | 104 | 0.100 |
Why?
| | Mice, Transgenic | 2 | 2012 | 1947 | 0.100 |
Why?
| | Inflammation | 1 | 2022 | 2464 | 0.100 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2012 | 26 | 0.100 |
Why?
| | Haplotypes | 1 | 2014 | 448 | 0.100 |
Why?
| | Disease Progression | 2 | 2017 | 2371 | 0.100 |
Why?
| | Receptors, Virus | 1 | 2012 | 75 | 0.100 |
Why?
| | Protein Transport | 1 | 2013 | 391 | 0.100 |
Why?
| | Humans | 9 | 2022 | 114043 | 0.100 |
Why?
| | RNA, Messenger | 2 | 2013 | 2550 | 0.100 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2014 | 222 | 0.100 |
Why?
| | Leukocyte Common Antigens | 1 | 2011 | 75 | 0.100 |
Why?
| | NF-kappa B | 2 | 2008 | 636 | 0.090 |
Why?
| | Brain Ischemia | 1 | 2014 | 297 | 0.090 |
Why?
| | Interleukin-2 | 1 | 2012 | 413 | 0.090 |
Why?
| | Heart Arrest | 1 | 2014 | 293 | 0.090 |
Why?
| | Benzimidazoles | 1 | 2011 | 137 | 0.090 |
Why?
| | Cell Nucleus | 1 | 2013 | 552 | 0.090 |
Why?
| | Prediabetic State | 1 | 2013 | 219 | 0.090 |
Why?
| | Glycosylation | 1 | 2010 | 130 | 0.090 |
Why?
| | Molecular Weight | 1 | 2010 | 328 | 0.090 |
Why?
| | Bleomycin | 1 | 2011 | 228 | 0.080 |
Why?
| | Down-Regulation | 1 | 2012 | 594 | 0.080 |
Why?
| | DNA Primers | 1 | 2010 | 508 | 0.080 |
Why?
| | Protein Isoforms | 1 | 2010 | 337 | 0.080 |
Why?
| | bcl-X Protein | 1 | 2008 | 38 | 0.080 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2008 | 20 | 0.080 |
Why?
| | Magnetics | 1 | 2008 | 39 | 0.080 |
Why?
| | Protein Binding | 1 | 2013 | 1888 | 0.070 |
Why?
| | Pulmonary Fibrosis | 1 | 2011 | 321 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2006 | 1695 | 0.070 |
Why?
| | Receptors, Chemokine | 1 | 2007 | 44 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2012 | 3861 | 0.070 |
Why?
| | HIV Infections | 1 | 2021 | 2453 | 0.070 |
Why?
| | Time Factors | 1 | 2017 | 6077 | 0.070 |
Why?
| | Cell Death | 1 | 2008 | 322 | 0.070 |
Why?
| | Base Sequence | 1 | 2010 | 2114 | 0.070 |
Why?
| | Adolescent | 3 | 2021 | 17800 | 0.070 |
Why?
| | Antigens, CD | 1 | 2008 | 440 | 0.070 |
Why?
| | HLA Antigens | 1 | 2007 | 220 | 0.060 |
Why?
| | Brain | 1 | 2017 | 2355 | 0.060 |
Why?
| | Homeostasis | 1 | 2008 | 570 | 0.060 |
Why?
| | Young Adult | 2 | 2021 | 10444 | 0.060 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 2003 | 11 | 0.050 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2003 | 18 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2007 | 1981 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 2023 | 242 | 0.050 |
Why?
| | Adult | 3 | 2021 | 30375 | 0.050 |
Why?
| | Double-Blind Method | 1 | 2007 | 1656 | 0.050 |
Why?
| | Clone Cells | 1 | 2003 | 247 | 0.050 |
Why?
| | DNA, Complementary | 1 | 2003 | 255 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2783 | 0.050 |
Why?
| | Cloning, Molecular | 1 | 2003 | 522 | 0.050 |
Why?
| | Pancreas | 1 | 2004 | 276 | 0.050 |
Why?
| | Th1 Cells | 1 | 2002 | 123 | 0.050 |
Why?
| | North Carolina | 1 | 2021 | 83 | 0.050 |
Why?
| | Middle Aged | 2 | 2014 | 26605 | 0.050 |
Why?
| | Thymus Gland | 1 | 2002 | 296 | 0.050 |
Why?
| | Male | 4 | 2021 | 55396 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2007 | 3003 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2021 | 169 | 0.040 |
Why?
| | Lung | 1 | 2011 | 3521 | 0.040 |
Why?
| | Universities | 1 | 2021 | 338 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2008 | 1846 | 0.030 |
Why?
| | Students | 1 | 2021 | 499 | 0.030 |
Why?
| | Aged | 1 | 2014 | 18969 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2014 | 274 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2021 | 1168 | 0.030 |
Why?
| | Cytological Techniques | 1 | 2011 | 24 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 4402 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 191 | 0.020 |
Why?
| | Hippocampus | 1 | 2014 | 690 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4595 | 0.020 |
Why?
| | Lung Injury | 1 | 2011 | 192 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 990 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2008 | 293 | 0.020 |
Why?
| | Up-Regulation | 1 | 2008 | 802 | 0.020 |
Why?
| | Models, Statistical | 1 | 2008 | 595 | 0.010 |
Why?
| | Software | 1 | 2008 | 527 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2629 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 1257 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2011 | 1736 | 0.010 |
Why?
| | Cohort Studies | 1 | 2008 | 4883 | 0.010 |
Why?
|
|
Wagner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|